Skip to main navigation

About Us
Our Approach
& Programs
Patients
& Caregivers
For Investors
& Media
Join
Our Team
- Who We Are
- Benefits
- Join Us
- Awards
Contact

About Us
Our Approach
& Programs
Patients
& Caregivers
For Investors
& Media
Join
Our Team
- Who We Are
- Benefits
- Join Us
- Awards
Contact

Investors & Media

Investor Overview
Stock Information
- Stock Quote
- Stock Chart
Press Releases
Events and Presentations
Corporate Governance
Financial Information
- SEC Filings
Annual Reports
Analyst Coverage
Investor FAQs
Contact Us

Press Releases

Keyword Search

Year

Aug 9, 2019

Voyager Therapeutics Reports Second Quarter 2019 Financial Results and Corporate Highlights

Aug 5, 2019

Voyager Therapeutics to Host Second Quarter 2019 Financial Results and Corporate Highlights Conference Call

Jul 30, 2019

Voyager Therapeutics to Present at Upcoming Investor Conferences in August 2019

Jun 17, 2019

Voyager Therapeutics Announces Restructured Gene Therapy Relationship with Sanofi Genzyme and Portfolio Update

Jun 11, 2019

Voyager Therapeutics to Present at the Raymond James Life Sciences & MedTech Conference

May 20, 2019

Voyager Therapeutics Announces Management Updates

May 7, 2019

Voyager Therapeutics Reports First Quarter 2019 Financial Results and Corporate Highlights

May 5, 2019

Neurocrine Biosciences and Voyager Therapeutics Announce Phase I Results for VY-AADC in Patients with Parkinson’s Disease at the American Academy of Neurology Annual Meeting

Apr 29, 2019

Voyager Therapeutics Announces New Data in Multiple Presentations at the American Society of Gene and Cell Therapy 2019 Annual Meeting

Apr 15, 2019

Voyager Therapeutics Announces Upcoming Data Presentations at the American Society of Gene and Cell Therapy 2019 Annual Meeting

Apr 3, 2019

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 (c)(4)

Apr 2, 2019

Voyager Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference

Mar 28, 2019

Neurocrine Biosciences and Voyager Therapeutics Announce Publication of Phase 1b Trial Results of VY-AADC for Parkinson’s Disease in the Annals of Neurology

Feb 26, 2019

Voyager Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Corporate Highlights

Feb 22, 2019

Voyager Therapeutics and AbbVie Announce Collaboration to Develop Vectorized Antibodies to Treat Parkinson’s Disease and Other Synucleinopathies

Feb 19, 2019

Voyager Therapeutics to Present at Upcoming Investor Conferences

Feb 18, 2019

Voyager Therapeutics to Host Fourth Quarter and Full Year 2018 Financial Results and Corporate Highlights Conference Call

Jan 29, 2019

Neurocrine Biosciences and Voyager Therapeutics Form Strategic Development and Commercialization Collaboration for Parkinson’s Disease and Friedreich’s Ataxia

Jan 22, 2019

Voyager Therapeutics Appoints Robert Hesslein as General Counsel

Jan 15, 2019

Voyager Therapeutics to Appoint Omar Khwaja, M.D., Ph.D., as Chief Medical Officer

Jan 7, 2019

Voyager Therapeutics Provides Updates for VY-AADC Clinical Program for Parkinson’s Disease

Print Page
RSS Feeds
Share Page
X
- Share on:
- Facebook
- Twitter
- LinkedIn
- Google+
- Reddit
- Digg
- Google
- Delicious
- StumbleUpon
E-mail Alerts
IR Contacts

Data provided by Nasdaq. Minimum 15 minutes delayed.

About Us
Our Approach
& Programs
Patients
& Caregivers
For Investors
& Media
Join Our
Team
Contact

© Voyager Therapeutics All rights served.

LinkedIn
Terms of Use
Sitemap